Co-effect of insulin resistance and biomarkers of inflammation and endothelial dysfunction on hypertension

Hypertension Research

Volumn 35, Issue 5, 2012, Pages 513-517

  Li, Hongmei ^a   Zhu, Xiaohong ^a,b   Wang, Aili ^a   Wang, Guiyan ^a,c   Zhang, Yonghong ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b Department of Epidemiology   (China)

^c Xiamen Maternal and Child Care Hospital   (China)

Author keywords

Endothelial dysfunction; Inflammation; Insulin resistance

Indexed keywords

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASIAN; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MONGOLIA; MULTICENTER STUDY; OBESITY; PREVALENCE; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; ANGIOTENSIN II; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PREVALENCE; RISK;

EID: 84860757067     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.229     Document Type: Article

References (42)

1. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential hypertension. J Hypertens 1995; 17: 1457-1462.
2. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.
3. Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S, Zaccaro D, Bergman RN, Savage PJ, Haffner SM. Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis Study. Hypertension 2004; 43: 1-8.
4. Ferrari P, Weidmann P. Insulin, insulin sensitivity and hypertension. J Hypertens 1990; 8: 491-500.
5. Hirose H, Saito I, Kawabe H, Sarita T. Insulin resistance and hypertension: seven-year follow-up study in middle-aged Japanese men (the KEIO study). Hypertens Res 2003; 26: 795-800.
6. Anuurad E, Tracy RP, Pearson TA, Kim K, Berglund L. Synergistic role of inflammation and insulin resistance as coronary artery disease risk factors in African Americans and Caucasians. Atherosclerosis 2009; 205: 290-295.
7. Park K, Steffes M, Lee DH, Himes JH, Jacobs Jr DR. Association of inflammation with worsening HOMA-insulin resistance. Diabetologia 2009; 52: 2337-2344.
8. Chen NG, Holmes M, Reaven GM. Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Endocrinol Metab 1999; 84: 3485-3489.
9. Valle Jiménez M, Estepa RM, Camacho RM, Estrada RC, Luna FG, Guitarte FB. Endothelial dysfunction is related to insulin resistance and inammatory biomarker levels in obese prepubertal children. Eur J Endocrinol 2007; 156: 497-502.
10. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46: S9-S13.
11. Perticone F, Sciacqua A, Scozzafava A, Ventura G, Laratta E, Pujia A, Federici M, Lauro R, Sesti G. Impaired endothelial function in never treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. J Clin Endocrinol Metab 2004; 89: 3606-3609.
12. Festa A, D'Agostino Jr R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
13. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
14. Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen MR. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003; 166: 384-394.
15. Hossain M, Faruque MO, Kabir G, Hassan N, Sikdar D, Nahar Q, Ali L. Association of serum TNF-a and IL-6 with insulin secretion and insulin resistance in IFG and IGT subjects in a Bangladeshi population. Int J Diabetes Mellit 2010; 2: 165-168.
16. Perticone F, Maio R, Sciacqua A, Andreozzi E, Iemma G, Perticone M, Zoccali C, Sesti G. Endothelial dysfunction and C-reactive protein are risk factors for diabetes in essential hypertension. Diabetes 2008; 57: 167-171.
17. Sheu WH, Jeng CY, Shieh SM, Fuh MM, Shen DD, Chen YD, Reaven GM. Insulin resistance and abnormal electrocardiograms in patients with high blood pressure. Am J Hypertens 1992; 5: 444-448.
18. Lima NKC, Abbasi F, Lamendola C, Reaven GM. Prevalence of insulin resistance and related risk factors for cardiovascular disease in patients with essential hypertension. Am J Hypertens 2009; 22: 106-111.
19. Cooperative Meta-analysis Group of China Obesity Task Force. Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population. Chin J Epidemiol (in Chinese) 2002; 23: 5-10.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
21. Haber E, Koerner T, Page LB, Kliman B, Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 1969; 29: 1349-1355.
22. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129-2138.
23. Emanuel RL, Cain JP, Williams GH. Double antibody radioimmunoassay of renin activity and angiotensin II in human peripheral plasma. J Lab Clin Med 1973; 81: 632-640.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner R. Homeostatic model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
25. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol 2008; 103: 398-406.
26. Szmitko PE, Wang CH, Weisel RD, Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation, Part I. Circulation 2003; 108: 1917-1923.
27. Ridker PM, Hennekens CH, Buring JE, Rifal N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
28. Schiffrin EL, Touyz RM. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade. J Am Coll Cardiol 2003; 42: 911-913.
29. Pastore L, Tessitore A, Martinotti S, Toniato E, Alesse E, Bravi MC, Ferri C, Desideri G, Gulino A, Santucci A. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100: 1646-1652.
30. Ndumele CE, Pradhan AD, Ridker PM. Interrelationships between inflammation, C-reactive protein, and insulin resistance. J Cardiometab Syndr 2006; 1: 190-196.
31. Gelaye B, Revilla L, Lopez T, Suarez L, Sanchez SE, Hevner K, Fitzpatrick AL, Williams MA. Association between insulin resistance and C-reactive protein among Peruvian adults. Diabetol Metab Syndr 2010; 2: 30-35.
32. Hsua LA, Kob YL, Wu S, Teng MS, Chou HH, Chang CJ, Chang PY. Association of soluble intercellular adhesion molecule-1 with insulin resistance and metabolic syndrome in Taiwanese. Metabolism 2009; 58: 983-988.
33. Ingelsson E, Hulthe J, Lind L. Inflammatory markers in relation to insulin resistance and the metabolic syndrome. Eur J Clin Invest 2008; 38: 502-509.
34. Xu JW, Morita I, Ikeda K, Miki T, Yamori Y. C-reactive protein suppresses insulin signaling in endothelial cells: role of spleen tyrosine kinase. Mol Endocrinol 2007; 21: 564-573.
35. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
36. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep 2003; 3: 279-288.
37. Anuurad E, Tracy SP, Pearson TA, Kim K, Berglund L. Synergistic role of inflammation and insulin resistance as coronary artery disease risk factors in African Americans and Caucasians. Atherosclerosis 2009; 205: 290-295.
38. Matsumoto K, Fujita N, Ozaki M, Tominaga T, Ueki Y, Miyake S. Coexistence of insulin resistance and inflammation effectively predicts cardiac disease but not stroke in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2006; 74: 316-321.
39. Fogari R, Zoppi A, Corradi L, Preti P, Mugellini A, Lazzari P, Derosa G. Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension. Hypertens Res 2010; 33: 236-242.
40. Hamdy O, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Caselli A, Caballero AE, Economides PA, Veves A, Horton ES. Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003; 26: 2119-2125.
41. Fogari R, Zoppi A, Salvadeo SA, Mugellini A, Lazzari P, Santoro T, Derosa G. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. Hypertens Res 2011; 34: 509-515.
42. Derosa G, Salvadeo SAT. Endothelial function, blood pressure control, and risk modification: impact of irbesartan alone or in combination. Integr Blood Press Control 2010; 3: 21-30.